Virax Biolabs Group Ltd
VRAX
$0.65
Closing
▼-1.06%
1D
▼-56.31%
YTD
Market cap
$1.57M
52 week high
$5.40
52 week low
$0.61
Volume
1,155
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$1.57M
Analysts' Rating
-
Price Target (Mean)
2
Total Analysts
0
P/E
Operating Margin
0.00%
Beta
Revenue Growth (Annual)
-100.00%
52 week high
$5.40
52 week low
$0.61
Div. Yield
%
EPS Annual Growth
0.00
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Virax Biolabs Group Limited is a biotechnology company. The Company is primarily engaged in the sales, distribution and marketing of diagnostics test kits and medical technology for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. It is developing a T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral threats. Its product portfolio includes: ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.
